FIG 8 .

OVA-specific and Invaplex_NAT-specific serum IgG endpoint titers in mice after intranasal immunization with OVA alone or OVA combined with Invaplex_AR, Invaplex_NAT, or cholera toxin (CT). Groups of mice were intranasally immunized on days 0, 14, and 28 with OVA or OVA combined with either S. flexneri 2a Invaplex_AR or Invaplex_NAT or CT. Blood collected on days 0, 28, and 42 was analyzed by ELISA for anti-OVA and anti-Invaplex_NAT serum IgG endpoint titers. Lung washes collected on day 42 were analyzed by ELISA for anti-OVA and anti-Invaplex_NAT IgA endpoint titers. Data represent the mean (n = 5 mice/group) endpoint titer ± 1 standard error of the mean. Significant differences between group mean log-transformed titers were determined by two-way analysis of variance (P < 0.05).